Status:
COMPLETED
Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study
Lead Sponsor:
LMC Diabetes & Endocrinology Ltd.
Conditions:
T2DM (Type 2 Diabetes Mellitus)
Fatty Liver
Eligibility:
All Genders
18+ years
Brief Summary
The primary objective of this study is to investigate the change in Alanine Aminotransaminase (ALT) in patients with Type 2 Diabetes Mellitus (T2DM) initiating Sodium Glucose Cotransporter 2 (SGLT2) i...
Detailed Description
Non-alcoholic fatty liver disease (NAFLD) is very commonly associated with type 2 diabetes mellitus (T2DM) 1. Alanine aminotransferase (ALT) is a common biomarker used to predict levels of NAFLD. The ...
Eligibility Criteria
Inclusion
- Diagnosis of T2DM based upon historical clinical diagnosis
- Patients who initiated canagliflozin, dapagliflozin, liraglutide or sitagliptin by an LMC physician between January 2011 and December 2015, or patients who did not initiate a new diabetes therapy between June 2014 and June 2015.
Exclusion
- Diagnosis of type 1 diabetes
- Patients who switched to one of the study treatments from another medication of the same medication class
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2017
Estimated Enrollment :
4000 Patients enrolled
Trial Details
Trial ID
NCT03233178
Start Date
January 1 2017
End Date
June 1 2017
Last Update
July 28 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
LMC Brampton
Brampton, Ontario, Canada, L6S 0C9